Jindike Responds to Stock Price Limit-Down: Trivalent Influenza Vaccine Packaging Has Begun; Specific Launch Date Depends on Batch Release Progress

On October 12, Jindike's stock hit a 20% limit-down amid negative news regarding potential delisting risk warnings. The company's board secretary office stated that it has timely disclosed relevant matters in compliance with the CSRC and SSE requirements, with no other undisclosed major information. Regarding the trivalent influenza vaccine, packaging has commenced, but the specific launch date for sales will depend on batch release progress. Additionally, addressing concerns about whether the quadrivalent influenza vaccine is being temporarily suspended or discontinued entirely, Jindike clarified that the World Health Organization releases forecasts for the Northern Hemisphere flu season in early January, and China's CDC issues corresponding vaccination guidelines in July-August; final decisions will be based on annual circumstances. (Beijing Business Review)